347 related articles for article (PubMed ID: 17704793)
41. A simplified method of CD34+ cell determination for peripheral blood progenitor cell transplantation and correlation with clinical engraftment.
Sandhaus LM; Edinger MG; Tubbs RR; Goormastic M; Baucco PA; Serafino SE; Bolwell BJ
Exp Hematol; 1998 Jan; 26(1):73-8. PubMed ID: 9430516
[TBL] [Abstract][Full Text] [Related]
42. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation.
Pérez-Simón JA; Martín A; Caballero D; Corral M; Nieto MJ; Gonzalez M; Vazquez L; López-Berges C; Cañizo MC; Mateos MV; Orfao A; San Miguel JF
Bone Marrow Transplant; 1999 Dec; 24(12):1279-83. PubMed ID: 10627635
[TBL] [Abstract][Full Text] [Related]
43. CD34+/CD41a+ cells best predict platelet recovery after autologous peripheral blood stem cell transplantation.
Feng R; Shimazaki C; Inaba T; Takahashi R; Hirai H; Kikuta T; Sumikuma T; Yamagata N; Ashihara E; Fujita N; Nakagawa M
Bone Marrow Transplant; 1998 Jun; 21(12):1217-22. PubMed ID: 9674855
[TBL] [Abstract][Full Text] [Related]
44. Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony-forming unit-granulocyte-macrophage, or both?
Jansen EM; Hanks SG; Terry C; Akard LP; Thompson JM; Dugan MJ; Jansen J
Transfusion; 2007 May; 47(5):817-23. PubMed ID: 17465946
[TBL] [Abstract][Full Text] [Related]
45. Analysis of parameters affecting engraftment in children undergoing autologous peripheral blood stem cell transplants.
Figuerres E; Haut PR; Olzewski M; Kletzel M
Bone Marrow Transplant; 2000 Mar; 25(6):583-8. PubMed ID: 10734291
[TBL] [Abstract][Full Text] [Related]
46. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
47. Kinetics and immunophenotypic characterization of circulating hematopoietic progenitor cells after peripheral blood stem cell transplantation.
Albo C; de la Fuente J; Ares C; Alonso C; Feteira E
Haematologica; 2004 Jul; 89(7):845-51. PubMed ID: 15257937
[TBL] [Abstract][Full Text] [Related]
48. Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.
Leong CF; Habsah A; Teh HS; Goh KY; Fadilah SA; Cheong SK
Malays J Pathol; 2008 Jun; 30(1):31-6. PubMed ID: 19108409
[TBL] [Abstract][Full Text] [Related]
49. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
Oran B; Malek K; Sanchorawala V; Wright DG; Quillen K; Finn KT; La Valley M; Skinner M; Seldin DC
Bone Marrow Transplant; 2005 Mar; 35(6):567-75. PubMed ID: 15665842
[TBL] [Abstract][Full Text] [Related]
50. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
51. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss.
Maclean PS; Parker AN; McQuaker IG; Clark AD; Farrell E; Douglas KW
Bone Marrow Transplant; 2007 Oct; 40(7):665-9. PubMed ID: 17646841
[TBL] [Abstract][Full Text] [Related]
52. Peripheral blood and BM CD34+ CD38- cells show better resistance to cryopreservation than CD34+ CD38+ cells in autologous stem cell transplantation.
Ojeda-Uribe M; Sovalat H; Bourderont D; Brunot A; Marr A; Lewandowski H; Chabouté V; Peter P; Henon P
Cytotherapy; 2004; 6(6):571-83. PubMed ID: 15764022
[TBL] [Abstract][Full Text] [Related]
53. Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation.
Statkute L; Verda L; Oyama Y; Traynor A; Villa M; Shook T; Clifton R; Jovanovic B; Satkus J; Loh Y; Quigley K; Yaung K; Gonda E; Krosnjar N; Spahovic D; Burt RK
Bone Marrow Transplant; 2007 Mar; 39(6):317-29. PubMed ID: 17277794
[TBL] [Abstract][Full Text] [Related]
54. Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies.
Bolwell BJ; Pohlman B; Rybicki L; Sobecks R; Dean R; Curtis J; Andresen S; Koo A; Mineff V; Kalaycio M; Sweetenham JW
Bone Marrow Transplant; 2007 Sep; 40(5):437-41. PubMed ID: 17618321
[TBL] [Abstract][Full Text] [Related]
55. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies.
Putkonen M; Rauhala A; Pelliniemi TT; Remes K
Ann Hematol; 2009 Jul; 88(7):673-80. PubMed ID: 19139894
[TBL] [Abstract][Full Text] [Related]
56. Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells.
Akkök CA; Holte MR; Tangen JM; Ostenstad B; Bruserud O
Transfusion; 2009 Feb; 49(2):354-61. PubMed ID: 18980622
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.
Gurkan E; Patah PA; Saliba RM; Ramos CA; Anderson BS; Champlin R; de Lima M; Lichtiger B
Bone Marrow Transplant; 2007 Sep; 40(5):461-4. PubMed ID: 17589530
[TBL] [Abstract][Full Text] [Related]
58. CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation.
Oyekunle A; Koehl U; Schieder H; Ayuk F; Renges H; Fehse N; Zabelina T; Fehse B; Klingebiel T; Sputtek A; Zander A; Kröger N
Cytotherapy; 2006; 8(4):375-80. PubMed ID: 16923613
[TBL] [Abstract][Full Text] [Related]
59. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma.
Tomblyn M; Burns LJ; Blazar B; Wagner J; Lee C; Rogers T; McGlave P; Miller JS; Weisdorf DJ
Bone Marrow Transplant; 2007 Jul; 40(2):111-8. PubMed ID: 17530003
[TBL] [Abstract][Full Text] [Related]
60. Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization.
Fu P; Bagai RK; Meyerson H; Kane D; Fox RM; Creger RJ; Cooper BW; Gerson SL; Laughlin MJ; Koc ON; Lazarus HM
Bone Marrow Transplant; 2006 Aug; 38(3):189-96. PubMed ID: 16850032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
